PREFERRED-1 is a pilot study for a large randomized, pragmatic, open-label,
comparative-effectiveness trial. The pilot will enroll at least 60 patients across 6
different hemodialysis centres in Ontario, Canada. Patients on outpatient maintenance
hemodialysis at high risk of fragility fracture will be randomized 1:1 to denosumab vs.
no-denosumab (i.e. usual care).
Phase:
Phase 4
Details
Lead Sponsor:
Western University, Canada
Collaborators:
Academic Medical Organization of Southwestern Ontario ICES The Kidney Foundation of Canada Western University